Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.

Minoru MiyashitaMasaya HattoriToshimi TakanoTatsuya ToyamaHiroji Iwata

Published in: Breast cancer (Tokyo, Japan) (2020)

Compared to chemotherapy alone, bevacizumab combined with chemotherapy significantly improved PFS in the HER2-negative MBC patients. However, the lack of a significant OS difference remained.

Keyphrases

metastatic breast cancer
locally advanced
end stage renal disease
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
squamous cell carcinoma
metastatic colorectal cancer
patient reported outcomes
risk assessment